Drug Development Pipeline Explained: From Lab to Pharmacy Shelf
It takes 10 to 15 years and over a billion dollars to bring a single new drug to patients, and only a tiny fraction of starting compounds ever gets there. The Clarity Clinical Solutions video "Drug Development Pipeline Explained: From Lab to Pharmacy Shelf" follows the journey from lab bench to pharmacy shelf, phase by phase. This article walks the same pipeline, with the FDA's own descriptions of each step.
Discovery: finding a molecule that might work
Before a drug can be tested, scientists have to find a molecule that might do something useful. The discovery phase starts with target identification: researchers identify a biological target, usually a protein or gene, that plays a key role in a disease. Then comes hit-to-lead screening, where thousands of compounds are tested against the target and a few dozen promising ones are refined into leads. Lead optimization modifies the molecule to improve potency and reduce toxicity. Modern techniques use computer modeling and AI to design molecules that fit the target like a key in a lock. Discovery alone takes three to five years.
Preclinical testing: no humans yet
Preclinical testing happens before any human sees the drug. First, in vitro testing on cells and tissues in a dish asks whether the drug kills cancer cells, say, or damages healthy ones. Then in vivo testing in at least two animal species studies pharmacokinetics, how the body absorbs and eliminates the drug, plus toxicology at high doses. Finally, formulation development turns the compound into a pill or injection. Preclinical work takes three to six years, and only about one in a thousand candidate compounds survives it.
The IND: the gateway to human testing
To test a drug in people, a sponsor files an investigational new drug application (IND) with the FDA. The IND contains the animal data showing the drug is reasonably safe, manufacturing information, the Phase I protocol, and investigator qualifications. The FDA has 30 days to review it; if the agency does not place a clinical hold, the sponsor can begin (FDA on the IND application). The video puts the pass rate at about 85 percent.
Phase I: is it safe?
Phase I is the first time the drug is tested in humans. Typically 20 to 100 healthy volunteers receive the drug in escalating doses. The goal is not to see whether the drug works; it is to find the maximum tolerated dose and understand the safety profile. Phase I takes six to 12 months. About 70 percent of drugs pass; the rest are abandoned because of liver damage, heart problems, or other unacceptable side effects. The FDA's own description of the clinical research step covers all three phases (FDA Step 3: Clinical Research).
Phase II: does it work?
Phase II enrolls 100 to 500 patients with the target disease at multiple dose levels. This is a dose-ranging study designed to find the optimal dose: high enough to work, low enough to tolerate. Patients are randomized and blinded. Phase II takes one to two years, and only about a third of drugs pass. It is the biggest attrition point in the entire pipeline, the place where most drugs fail.
Phase III: prove it
Phase III is the large, definitive test: 1,000 to 5,000 patients across multiple countries and dozens of sites, randomized, double-blind, and placebo-controlled. The goal is to show the drug is statistically significantly better than placebo or the current standard of care. Phase III takes two to four years and can cost over $100 million per trial, which is why most programs run two large confirmatory trials at once. About 50 to 60 percent of drugs that enter Phase III succeed.
NDA review: the FDA decides
After successful Phase III trials, the sponsor submits a new drug application (NDA) containing all preclinical and clinical data, manufacturing details, and proposed labeling (FDA on the NDA). An NDA can run over 100,000 pages. Standard review takes 10 to 12 months; priority review for breakthrough drugs takes 6 to 8. Inside the FDA, a multidisciplinary team of 10 to 20 experts does the work: medical officers review clinical data, pharmacologists review safety, biostatisticians verify the statistics (FDA Step 4: FDA Drug Review). For most new drugs, an independent advisory committee of external experts votes, and the FDA makes the final call. The three possible outcomes: approval, a complete response letter asking for more data, or refusal. The FDA approves roughly 40 to 50 new drugs a year in the US, and the overall success rate from Phase I to approval is about 7 to 10 percent.
Phase IV: approval is not the end
Once a drug is on the market, Phase IV, post-market surveillance, begins. The FDA monitors the drug through its adverse event reporting system, which anyone can use to report a side effect (FDA Adverse Event Reporting System). The agency can require additional studies to answer long-term safety questions. If new safety signals emerge, it can require label changes, add boxed warnings, or in extreme cases withdraw the drug from the market (FDA Step 5: Post-Market Drug Safety Monitoring). The video estimates that 3 to 5 percent of approved drugs are eventually withdrawn for safety reasons.
Why drugs cost so much
The full timeline, discovery to patient, runs 10 to 15 years if everything goes right. The Tufts Center for the Study of Drug Development has long estimated the cost of developing one approved drug at $1.3 to $2.6 billion, and that number includes the cost of all the failures along the way (Tufts CSDD). Preclinical work accounts for about 30 percent of the cost, Phase I about 10 percent, Phase II about 20 percent, and Phase III about 30 percent. That is why new drugs are expensive, and why companies concentrate on diseases where they can recoup the investment.
Why most drugs fail
Lack of efficacy causes 30 to 40 percent of failures: the drug simply does not work in humans. Safety and toxicity cause 25 to 30 percent: unacceptable side effects. Poor pharmacokinetics cause 10 to 15 percent: the drug never reaches its target. The biggest filter comes early. From preclinical to Phase I, 70 percent pass. From Phase I to Phase II, only 33 percent. Phase II to Phase III, 50 to 60 percent. Phase III to approval, 85 to 90 percent.
The bottom line
Discovery, preclinical testing, three phases of human trials, FDA review, and post-market monitoring: that is the pipeline, and it runs 10 to 15 years and one to two billion dollars per success. Of 10,000 starting compounds, one reaches patients. Every pill in your cabinet made this journey, which is exactly why regulators, sponsors, and patients all treat the path with such care.
This article is based on the Clarity Clinical Solutions video "Drug Development Pipeline Explained: From Lab to Pharmacy Shelf." Watch it here: Drug Development Pipeline Explained: From Lab to Pharmacy Shelf
References
- Clarity Clinical Solutions — "Drug Development Pipeline Explained: From Lab to Pharmacy Shelf" (source video). https://www.youtube.com/watch?v=Uzew2Brsv-Q
- FDA — Investigational New Drug (IND) Application. https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application
- FDA — Step 3: Clinical Research (drug development process). https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
- FDA — New Drug Application (NDA). https://www.fda.gov/drugs/types-applications/new-drug-application-nda
- FDA — Step 4: FDA Drug Review. https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
- FDA — FDA Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers
- FDA — Step 5: Post-Market Drug Safety Monitoring. https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring
- Tufts CSDD — Center for the Study of Drug Development (drug development cost research). https://csdd.tufts.edu/